Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Background
MT-1207 is a novel multitarget blocker of α1 receptor, 5-HT2A receptor, and calcium channel that is currently under development for the treatment of hypertension. In this study, we evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MT-1207 in healthy Chinese subjects.
Research design and methods
We examined the effects of a single-ascending dose (SAD) of MT-1207 (5–40 mg) and MT-1207 (40 mg) administered in combination with food in 56 healthy subjects.
Results
No serious adverse events or discontinuations due to adverse events (related to MT-1207) occurred in either study. MT-1207 was rapidly absorbed (median Tmax: 0.5–1.25 h). The mean t1/2 of MT-1207 was approximately 4–7 hours. Systemic exposure (Cmax and AUC) to MT-1207 …